- Home
- LXP vs APLS Comparison
LXP vs APLS Comparison
Compare LXP & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXP | APLS |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | United States | United States |
| Employees | 58 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | LXP | APLS |
|---|---|---|
| Price | $46.54 | $17.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $51.88 | $31.65 |
| AVG Volume (30 Days) | 526.2K | ★ 1.9M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.99% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $1.02 | N/A |
| Revenue Next Year | $7.42 | $18.21 |
| P/E Ratio | ★ $26.35 | $88.20 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $6.85 | $16.10 |
| 52 Week High | $52.52 | $30.48 |
Technical Indicators
Market Signals| Indicator | LXP | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.20 | 33.06 |
| Support Level | $8.52 | $17.16 |
| Resistance Level | $51.06 | $20.65 |
| Average True Range (ATR) | 1.14 | 0.68 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 34.96 | 25.11 |
Price Performance
Historical ComparisonAbout LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. The majority of the revenue is earned through rental revenue.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.